BioTrinity 2011: Company Showcase - Drug Discovery, Development and more 

---

The BioTrinity 2011 Company Showcase was a unique opportunity to take in up to 60 corporate/investor presentations from the best companies from the UK and Europe's most successful bioclusters and partner with them. This year we will again feature a mostly hand-selected line-up of the Most Promising Companies over April 24-26th 2012.   Day one will feature drug discovery and development (oncology, CNS, anti-infectives, anti-virals) as well as platform technologies, and Day Two will feature more drug discovery (inflammation and immunity), medtech as well as platform technology companies.  Presenting companies will include diagnostics and medical technology where that technology is directly relevant to therapeutics, including biomarkers and companion diagnostics.  Do contact us soon if you wish to be considered for one of presention slots, and do read details of the Selection Process below. 

Here is the listing of companies that presented in 2011:

Biotech Companies Showcasing

Wednesday, 13th April 2011

13:30-15:00 Oncology Track, Sponsored and Chaired by Shire

	13:30 Shire, Charlie Alexander, Director Business Development
	13:40 BioVex, Colin Love, SVP Development
	13:50 Chroma Therapeutics, Ian Nicholson, CEO
	14:00 Immunocore, James Noble, CEO
	14:10 e-Therapeutics plc, Malcolm Young, CEO
	14:20 PsiOxus, John Beadle, CEO
	14:30 Pro-Cure Therapeutics Ltd, Michael McLean, CEO
	14:40 PhotoBiotics, Elizabeth Rollinson, Director
	14:50 CellCentric, Will West, CEO
15:00-15:30 Refreshments, Networking & Exhibition
15:30-16:00 CNS/Neurology Track
	15:30 Oxford Biomedica, Peter Nolan, SVP Commercial Development
	15:40 Syntaxin Ltd, Phil Boyd, CFO
	15:50 Oryzon, Carlos Buesa, CEO
16:00-16:40 Anti-infectives / Anti Viral Track
	16:00 NovaBiotics, Deborah O'Neil, CEO
	16:10 Cell Medica, Gregg Sando, CEO
	16:20 Adaptimmune, Helen Tayton-Martin, COO
	16:30 ProCarta Biosystems, Michael McArthur, CSO
16:40-17:30 Inflammation / Autoimmunity Track
	16:40 Cellzome, Jane Dancer, VP Business Development
	16:50 Amakem NV, Jack Elands, CEO
	17:00 Apitope, Keith Martin, CEO
	17:10 Protaffin Biotechnologie, Jason Slingsby, CEO
	17:20 Critical Pharmaceuticals, Gareth King, CBO
Thursday 14th April 2011 11:30-12:30 Platform Technology and Service Track
	11:30 Bicycle Therapeutics, John Tite, CEO
	11:40 Phylogica, Paul Watt, CEO
	11:50 Morphosys AG, Susanne Krohn, Manager Business Development
	12:00 Cyprotex, Anthony Baxter, CEO
	12:10 Conformetrix, Gordon Barker, Commercial Director
	12:20 Crescendo Biologics, Mike Romanos, CEO
12:30-13:30 Lunch, Networking & Exhibition
13:30-14:10 Platform Technology and Service Track cont.
	13:30 Plasticell Therapeutics, Yen Choo, CEO
	13:40 Xention, Keith McCullagh, Chairman
	13:50 Oxford Expression Technology, Richard Broadhead, Sales & Marketing Manager
	14:00 SANIFIT Laboratoris, Ruben Henriquez, CEO
14:10-16:00 MedTech Track
	14:10 Introduction to MedTech Track, Chris Jones, CEO, Glysure
	14:20 BiOxyDyn, Hans von Celsing, CEO
	14:30 Orthox, Nick Skaer, CEO
	14:40 Michelson Diagnostics, Jon Holmes, CEO
	14:50 Future Injection Technologies, Paul Whyte, CEO
	15:00 Nanosight, Jeremy Warren, CEO
	15:10 Alchemy Healthcare, Alison Saunders, CEO
	15:20 nanoTherics, Linda Cammish, CEO
	15:30 Lumemed, Alan Whitmore, CEO/CMO
	15:40 OrganOx, Les Russell, CEO
	15:50 QSIant, Bruce Savage, Director

Overview of the company showcase

The majority of companies were hand-selected on the basis of their fundraising or revenue streams, USP, deal-making, innovation, and IP. The focus is on drug discovery and development, diagnostics and medical technology. The format of the presentations is an 8 minute presentation, including Q&A. Click on each speaker name to read biographies - further speaker biographies will be added as we receive them.

Selection Process

The vast majority of companies listed above are hand-picked by our team, although a small number of slots are reserved for applicants.  Please contact our CEO Jon Rees on +44 (0)845 5245 722 to discuss and apply for a speaking slot or make an Online Application. An informed decision will be made based upon information supplied by companies, business intelligence, potentially with reference to the expert knowledge of members of the OBN Advisory Board and our extended BioTrinity Advisory Board. As with other delegates, speakers from selected companies must complete a paid registration to be admitted and benefit from partnering at BioTrinity 2010.

Companies who are not selected to present are encouraged to participate in the one-to-one partnering elements of the meeting for the purposes of business development.

Criteria for Selection

• Consideration will be given to company's USP, or the USP of their leading product, the route-to-market, exit route and milestones.
• Consideration is given to revenue streams or demonstrated fund-raising ability, and proximity to market
• Efficient use of funding
• Recent deal-making success
• Innovation in product or business strategy
• Preference is given to companies based in the UK and Europe
• Preference is given to companies which have been trading for less than 7 years
• Intellectual property to meet business strategy